325 related articles for article (PubMed ID: 15936620)
1. Targeted inhibition of beta-adrenergic receptor kinase-1-associated phosphoinositide-3 kinase activity preserves beta-adrenergic receptor signaling and prolongs survival in heart failure induced by calsequestrin overexpression.
Perrino C; Naga Prasad SV; Patel M; Wolf MJ; Rockman HA
J Am Coll Cardiol; 2005 Jun; 45(11):1862-70. PubMed ID: 15936620
[TBL] [Abstract][Full Text] [Related]
2. Restoration of beta-adrenergic receptor signaling and contractile function in heart failure by disruption of the betaARK1/phosphoinositide 3-kinase complex.
Perrino C; Naga Prasad SV; Schroder JN; Hata JA; Milano C; Rockman HA
Circulation; 2005 May; 111(20):2579-87. PubMed ID: 15897344
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of betaARK1 restores impaired biochemical beta-adrenergic receptor responsiveness but does not rescue CREB(A133) induced cardiomyopathy.
Eckhart AD; Fentzke RC; Lepore J; Lang R; Lin H; Lefkowitz RJ; Koch WJ; Leiden JM
J Mol Cell Cardiol; 2002 Jun; 34(6):669-77. PubMed ID: 12054854
[TBL] [Abstract][Full Text] [Related]
4. Targeted inhibition of phosphoinositide 3-kinase activity as a novel strategy to normalize beta-adrenergic receptor function in heart failure.
Perrino C; Rockman HA; Chiariello M
Vascul Pharmacol; 2006 Aug; 45(2):77-85. PubMed ID: 16807128
[TBL] [Abstract][Full Text] [Related]
5. Phosphoinositide 3-kinase gamma-deficient mice are protected from isoproterenol-induced heart failure.
Oudit GY; Crackower MA; Eriksson U; Sarao R; Kozieradzki I; Sasaki T; Irie-Sasaki J; Gidrewicz D; Rybin VO; Wada T; Steinberg SF; Backx PH; Penninger JM
Circulation; 2003 Oct; 108(17):2147-52. PubMed ID: 12963636
[TBL] [Abstract][Full Text] [Related]
6. [Novel concepts in beta-adrenergic receptor signaling: therapeutic options for heart failure].
Schiattarella GG; Perrino C; Gargiulo G; Sorrentino S; Franzone A; Capretti G; Esposito G; Chiariello M
G Ital Cardiol (Rome); 2010 Mar; 11(3):221-8. PubMed ID: 20550062
[TBL] [Abstract][Full Text] [Related]
7. Targeted beta-adrenergic receptor kinase (betaARK1) inhibition by gene transfer in failing human hearts.
Williams ML; Hata JA; Schroder J; Rampersaud E; Petrofski J; Jakoi A; Milano CA; Koch WJ
Circulation; 2004 Apr; 109(13):1590-3. PubMed ID: 15051637
[TBL] [Abstract][Full Text] [Related]
8. In vivo inhibition of elevated myocardial beta-adrenergic receptor kinase activity in hybrid transgenic mice restores normal beta-adrenergic signaling and function.
Akhter SA; Eckhart AD; Rockman HA; Shotwell K; Lefkowitz RJ; Koch WJ
Circulation; 1999 Aug; 100(6):648-53. PubMed ID: 10441103
[TBL] [Abstract][Full Text] [Related]
9. Dynamic regulation of phosphoinositide 3-kinase-gamma activity and beta-adrenergic receptor trafficking in end-stage human heart failure.
Perrino C; Schroder JN; Lima B; Villamizar N; Nienaber JJ; Milano CA; Naga Prasad SV
Circulation; 2007 Nov; 116(22):2571-9. PubMed ID: 17998459
[TBL] [Abstract][Full Text] [Related]
10. Distinct beta-adrenergic receptor subtype signaling in the heart and their pathophysiological relevance.
Zheng M; Han QD; Xiao RP
Sheng Li Xue Bao; 2004 Feb; 56(1):1-15. PubMed ID: 14985822
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of receptor-localized PI3K preserves cardiac beta-adrenergic receptor function and ameliorates pressure overload heart failure.
Nienaber JJ; Tachibana H; Naga Prasad SV; Esposito G; Wu D; Mao L; Rockman HA
J Clin Invest; 2003 Oct; 112(7):1067-79. PubMed ID: 14523044
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of protein kinase C alpha improves myocardial beta-adrenergic receptor signaling and ventricular function in a model of myocardial preservation.
D'Souza KM; Petrashevskaya NN; Merrill WH; Akhter SA
J Thorac Cardiovasc Surg; 2008 Jan; 135(1):172-9, 179.e1. PubMed ID: 18179937
[TBL] [Abstract][Full Text] [Related]
13. Cardiac beta ARK1 inhibition prolongs survival and augments beta blocker therapy in a mouse model of severe heart failure.
Harding VB; Jones LR; Lefkowitz RJ; Koch WJ; Rockman HA
Proc Natl Acad Sci U S A; 2001 May; 98(10):5809-14. PubMed ID: 11331748
[TBL] [Abstract][Full Text] [Related]
14. Effects of two Gbetagamma-binding proteins--N-terminally truncated phosducin and beta-adrenergic receptor kinase C terminus (betaARKct)--in heart failure.
Li Z; Laugwitz KL; Pinkernell K; Pragst I; Baumgartner C; Hoffmann E; Rosport K; Münch G; Moretti A; Humrich J; Lohse MJ; Ungerer M
Gene Ther; 2003 Aug; 10(16):1354-61. PubMed ID: 12883532
[TBL] [Abstract][Full Text] [Related]
15. Level of beta-adrenergic receptor kinase 1 inhibition determines degree of cardiac dysfunction after chronic pressure overload-induced heart failure.
Tachibana H; Naga Prasad SV; Lefkowitz RJ; Koch WJ; Rockman HA
Circulation; 2005 Feb; 111(5):591-7. PubMed ID: 15668342
[TBL] [Abstract][Full Text] [Related]
16. Genetic and phenotypic targeting of beta-adrenergic signaling in heart failure.
Koch WJ
Mol Cell Biochem; 2004 Aug; 263(1-2):5-9. PubMed ID: 15524162
[TBL] [Abstract][Full Text] [Related]
17. What is the role of beta-adrenergic signaling in heart failure?
Lohse MJ; Engelhardt S; Eschenhagen T
Circ Res; 2003 Nov; 93(10):896-906. PubMed ID: 14615493
[TBL] [Abstract][Full Text] [Related]
18. Gene-mediated inhibition of the b-adrenergic receptor kinase: a new therapeutic strategy for heart failure.
Tevaearai HT; Eckhart AD; Koch WJ
Minerva Cardioangiol; 2001 Dec; 49(6):389-94. PubMed ID: 11733734
[TBL] [Abstract][Full Text] [Related]
19. Phosphoinositide 3-kinase gamma controls autonomic regulation of the mouse heart through Gi-independent downregulation of cAMP level.
Alloatti G; Marcantoni A; Levi R; Gallo MP; Del Sorbo L; Patrucco E; Barberis L; Malan D; Azzolino O; Wymann M; Hirsch E; Montrucchio G
FEBS Lett; 2005 Jan; 579(1):133-40. PubMed ID: 15620702
[TBL] [Abstract][Full Text] [Related]
20. Beta-adrenergic signaling in the heart: dual coupling of the beta2-adrenergic receptor to G(s) and G(i) proteins.
Xiao RP
Sci STKE; 2001 Oct; 2001(104):re15. PubMed ID: 11604549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
